Shares of Viatris Inc. (NASDAQ: VTRS) are down 3.67% in pre-market trading on Friday, July 18, 2025, with the stock price at $8.93. This follows a previous closing price of $9.27.
The decline comes after Viatris reported that its Phase 3 study of pimecrolimus 0.3% ophthalmic ointment for blepharitis failed to meet the primary endpoint of complete debris resolution after six weeks of twice-daily treatment.
